IMPORTANCE Warfarin use accounts for more medication-related emergency department visits among older patients than any other drug. Whether genotype-guided warfarin dosing can prevent these adverse events is unknown.
F or at least the last 10 years, warfarin use has accounted for more medication-related emergency department visits among older patients than any other drug. 1, 2 Warfarin dose requirements vary widely among individuals because of common single nucleotide polymorphisms (SNPs). 3, 4 Because knowledge of a patient's genotype should lead to more accurate warfarin initiation and a concomitant reduction in adverse events, the product label for warfarin (Coumadin and others) 5 has encouraged genotype-guided dosing since 2007. However, multicenter studies of genotype-guided dosing of oral vitamin K antagonists have had mixed results. [6] [7] [8] [9] [10] [11] [12] [13] [14] The 2 largest trials 7, 8 found no improvement in the primary end point of international normalized ratio (INR) control. In contrast, the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial of 445 patients found improved INR control with genotype-guided warfarin dosing. 9 Thus, it remains unclear whether genotype-guided dosing improves the safety of warfarin initiation. [6] [7] [8] [9] The goal of this multicenter randomized clinical trial was to determine whether genotype-guided warfarin dosing reduced adverse events.
Methods
The Genetic Informatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis was a multicenter randomized clinical trial of patients initiating warfarin at the time of elective hip or knee arthroplasty. 15 We used a 2 × 2 factorial design to randomize participants to genotype-guided or clinically guided dosing of warfarin on days 1 through 11 of therapy and to a target INR of 1.8 or 2.5. The results of genotype-guided vs clinically guided dosing of warfarin on days 1 through 11 of therapy are presented in this article (the trial protocol appears in Supplement 1). Patients were randomized 1:1 using a computerized system that stratified by site, type of arthroplasty (knee or hip), and race (black vs other). Randomization was stratified based on race because the CYP2C9*2 and CYP2C9*3 SNPs are less common among populations with African ancestry compared with other populations. 16 Race was self-identified using standard National Institutes of Health categories. The randomization sequence was generated by the WarfarinDosing.org webmaster at IsoDynamic.com. Participants and study personnel were blind to study group assignment and genotype; however, the warfarin dosing was open label. The study was approved by the institutional review boards at each site, the US Food and Drug Administration (FDA), and the US Centers for Medicare & Medicaid Services. All participants provided written informed consent in accordance with the Declaration of Helsinki.
Patients planning to undergo elective hip or knee arthroplasty who were aged 65 years or older and had a life expectancy of longer than 6 months were recruited for the trial. Exclusion criteria were patients with (1) a genotype or therapeutic warfarin dose known from prior therapy, (2) prior nonadherence, (3) contraindication to warfarin, (4) a treatment plan to receive an anticoagulant other than warfarin, (5) known thrombophilia, (6) a bleeding disorder, (7) a serious bleeding event within past 2 years (unless caused by trauma), (8) a baseline INR of 1.35 or greater, or (9) an additional indication for warfarin (eg, atrial fibrillation).
Trial Procedures
Testing for the INR was performed per standard practice. Warfarin was initiated either the night prior to arthroplasty (standard practice at Washington University in St Louis, St Louis, Missouri; University of Utah, Salt Lake City; and University of Texas Southwestern, Dallas) or the night of arthroplasty (standard practice at Hospital for Special Surgery, New York, New York; Intermountain Healthcare, Salt Lake City, Utah; and Rush University Medical Center, Chicago, Illinois). Except for dose recommendations, each study group was treated identically (with genotypes concealed in both groups).
A dose deviation was defined as a prescribed warfarin dose on days 1 through 11 of therapy that differed from the web application recommendation by 1.0 mg/d or greater (for doses >3 mg/d) or 0.5 mg/d or greater (for doses ≤3.0 mg/d). After day 11 of therapy, clinicians were free to continue the recommended warfarin dose or change it, depending on subsequent INR measures. Study participants underwent diagnostic testing in the event of signs or symptoms of deep vein thrombosis (DVT) or pulmonary embolism.
Participants who did not have a symptomatic venous thromboembolism (VTE) underwent bilateral duplex ultrasound screening approximately 1 month after arthroplasty. Ultrasonography was conducted and the ultrasounds were read by study personnel who were blinded to study group assignment.
AF22194) for patients randomized to genotype-guided dosing algorithms. 16, [19] [20] [21] SNPs in CYP2C9 determine S-warfarin metabolism 17 ; VKORC1, warfarin sensitivity 3 ; and CYP4F2, vitamin K metabolism. 18, 22 Blood for genotyping and archiving was obtained when it was drawn for the preoperative laboratory tests. Extraction of DNA from deidentified blood samples collected in EDTA tubes was performed to determine genotype for VKORC1*2 (-1639G>A, Short Genetic Variations database [dbSNP] rs9923231), CYP2C9*2 (430C>T, dbSNP rs1799853), CYP2C9*3 (1075A>C, dbSNP rs1057910), and CYP4F2*3 (V433M, 1297G>A, dbSNP rs2108622). Three clinical sites (Washington University in St Louis, University of Utah, and Intermountain Healthcare) performed local preoperative genotyping using GenMarkDx (formerly Osmetech) eSensor instrument and reagents, and using laboratory-developed real-time polymerase chain reaction methods (CYP4F2 only).
The central laboratory at Washington University in St Louis used the same methods to perform preoperative genotyping for the other 3 clinical sites (Hospital for Special Surgery, Rush University Medical Center, and University of Texas Southwestern). Once per month, the central laboratory also performed independent confirmatory genotyping using pyrosequencing or real-time polymerase chain reaction methods. Based on a trivial genotyping error rate (1 of 5689 SNPs), duplicate genotyping was discontinued in November 2013; thereafter, the central laboratory performed preoperative genotyping using the GenMarkDx platform for all sites.
Outcomes
The primary outcome of the study was a composite of the following adverse events: major bleeding within 30 days, INR of 4 or greater within 30 days, death within 30 days, and symptomatic or asymptomatic VTE confirmed by objective testing within 60 days of arthroplasty. Major bleeding was defined as (1) bleeding into a critical area (intracranial, epidural, intraocular, pericardial, or retroperitoneal), (2) overt bleeding that resulted in death, (3) a hematoma requiring a return to the operating room, (4) a decrease in hemoglobin level of 2 g/dL or greater, (5) a transfusion of 2 or more units of blood, or (6) hemodynamic changes requiring a transfusion of 1 or more units of blood. Bleeding that did not meet the major bleeding definition was further subclassified as nonmajor clinically relevant bleeding or minor bleeding that was not significant using the definition from prior anticoagulant trials. 7, 23, 24 Secondary outcomes were (1) adverse events; (2) the therapeutic warfarin dose; (3) INR control reported as the percentage of time in the therapeutic range (PTTR) calculated using linear interpolation 25 ; and (4) 90-day follow-up for the composite outcomes. When calculating the PTTR, an INR was considered in the target range if it was within the range of 2.0 to 3.0 for patients with a target INR of 2.5 and within the range of 1.5 to 2.1 for patients with a target INR of 1.8. 15 The same INR ranges were used when calculating the time to reach a therapeutic INR, which required that the subsequent INR (if any) measured at 1 week or longer also was within this target range without an intervening nontherapeutic INR. When 2 INR values were obtained on the same day, the mean was used.
Statistical Analyses
The study was analyzed on a modified intention-to-treat basis and included all randomized participants who received 1 or more doses of warfarin. In addition, we prespecified an analysis of the primary end point among patients in the high-risk subgroup whose clinically guided vs genotype-predicted doses differed by 1.0 mg/d or greater (according to baseline genotypeand clinically guided algorithms 16 ). To preserve a type I error rate of 5%, we partitioned the α value between the entire study population and the high-risk subgroup. Because the primary end points in the 2 groups were collinear, we used simulation to determine possible pairs of α values that preserved the overall type I error. 26 We selected an α value of .044 a priori for the primary outcome in the whole study population and an α value of .01 in the high-risk subgroup. We used an α value of .05 for other statistical testing.
To provide adequate power to detect a relative rate (RR) of 0.68 for the composite end point, we selected a sample size of 1600 participants. The RR estimate of 0.68 was selected based on a meta-analysis of clinical trials 27 and a large observational study. 28 The primary outcome was analyzed using the χ 2 test and confirmed using a generalized linear mixed model with site as a random effect. We calculated the rates (including for the post hoc analyses) by dividing the number of events by the total number of patients. We calculated the 95% CI for the absolute difference in rates using the method of Newcombe. 29 Secondary analyses of rare events (expected frequency ≤5) were analyzed using the Fisher exact test and after adding 0.5 as a continuity correction. We used logistic regression to test for an interaction between study group and these categories selected a priori: high-risk subgroup, black race, target INR of 1.8 vs 2.5, and CYP2C9 genotype. In the test of CYP2C9 genotype, we assigned 1 point for each CYP2C9*2 allele and 2 points for each CYP2C9*3 allele based on their effect on S-warfarin clearance.
We compared PTTR using an unpaired t test. Linear regression was used to test for an interaction between PTTR and target INR. For time to event analyses, we censored participants at the time of withdraw or loss to follow-up or 30 days after arthroplasty (whichever came first). For the time to therapeutic INR analysis, patients who had fewer than 24 days of INR monitoring were censored on the day of their last measured INR.
We compared the number of days until an INR exceeded the target INR by 1.5 using the log-rank test and the Cox proportional hazards model. For the Cox models, we confirmed the proportional hazard assumption by verifying that there was no interaction between predictor variables and time. All statistical tests were 2-sided. Statistical analyses were conducted using SAS analytical software version 9.4 (SAS Institute Inc) and R version 3.3.1 (R Project for Statistical Computing).
Results
Among 1650 patients (mean [SD] age 72.1 [5.4] years; 63.6% women; and 91.0% white), 831 (50.4%) were randomized to genotype-guided warfarin dosing and 819 (49.6%) to clinically guided warfarin dosing (eTable 1 in Supplement 2 and Figure 1 ). Enrollment began in April 2011 and patients were followed up for 90 days; follow-up of the final patient occurred in October 2016. Twenty-three patients in the genotypeguided group and 30 in the clinically guided group were excluded because they did not undergo arthroplasty, withdrew from the trial, never received warfarin, or were discovered to have met an exclusion criterion after randomization.
The patients who did not receive the intervention (eTable 1inSupplement 2) had a higher baseline INR compared with the included participants (1.03 vs 1.01, respectively) and were more likely to be smokers (9.4% vs 3.4%), scheduled for hip arthroplasty (45.3% vs 25.4%), and have a target INR of 2.5 (64.1% vs 49.7%). The final sample consisted of 1597 older participants who were predominantly white (91.1%) ( Table 1) , reflecting the arthroplasty population at the participating medical centers (59.2% of participants were recruited at the Hospital for Special Surgery). The genotype distribution was balanced between the 2 study groups ( Table 2) .
Primary Outcome
Eighty-seven of 808 participants (10.8%) in the genotypeguided group and 116 of 789 participants in the clinically guided group (14.7%) experienced at least 1 composite end point, corresponding to an absolute risk difference of 3.9% (95% CI, 0.7% to 7.2%; P = .02). The results for the genotype-guided dosing group were similar in the mixed model (P = .02). The rate difference for individual adverse events was 0.8% (95% CI, -0.2% to 1.8%) for major bleeding, 2.8% (95% CI, 0.1% to 5.6%) for INR of 4 or greater, and 0.7% (95% CI, -1.3% to 2.8%) for VTE ( Table 3) . None of the participants died.
The reduction in INR values of 4 or greater occurred after the first week of warfarin therapy ( Figure 2 ) and did not delay the time to reach a therapeutic INR (eFigure in Supplement 2). In the high-risk subgroup (n = 658; 41.2% of participants), the rates of the composite end point in the genotype-guided group vs the clinically guided group were 11.5% vs 15.2%, respectively, for an absolute difference of 3.76% (95% CI, -9.0% to 1.5%, P = .16). The benefit of genotype-guided dosing was consistent in that there was no significant interaction in any of the subgroups examined (high-risk subgroup, P = .88; black race, P =. 7 4;CYP2C9 genotype, P = .16; target INR of 1.8 vs 2.5, P = .70; or hip vs knee arthroplasty, P = .36).
Additional Clinical Outcomes
The rate of either major or nonmajor clinically relevant bleeding was 7.1% (57 events) in the genotype-guided group and 9.4% (74 events) in the clinically guided group for an absolute difference of 2.3% (95% CI, -0.4% to 5.1%; P = .09). KaplanMeier analysis confirmed that the risk of either major or nonmajor clinically relevant bleeding was similar ( Figure 3) . In a post hoc analysis, the rate of symptomatic major adverse events (major bleeding, symptomatic DVT, or pulmonary embolism) was 1.5% (12 events) in the genotype-guided group and 2.9% (23 events) in the clinically guided group (between-group difference, 1.4% [95% CI, 0%-3.0%]; P = .051). The rates of other adverse events (post hoc analyses) were similar in the 2 groups (eTable 2 and eFigure in Supplement 2).
Between the primary follow-up and day 90, there was 1 VTE in each group and 1 major bleeding event (an intracranial hemorrhage 2 months after stopping warfarin) in the clinically guided group. By day 90, the composite outcome (including INRs ≥4) had occurred in 90 participants (11.1%) in the genotype-guided group and 119 participants (15.1%) in the clinically guided group (between-group difference, 3.9% [95% CI, 0.6%-7.3%]; P = .02). The risk of an INR exceeding the target INR by 1.5 or greater was not significantly reduced in the genotype-guided group compared with the clinically guided group (hazard ratio, 0.78 [95% CI, 0.59-1.03]; log-rank test, P = .08).
Percentage of Time in the Therapeutic Range
The PTTR was calculable for 1588 participants ( Table 4) . Genotyping significantly (P = .004) improved PTTR by 3.4% a There were 1597 patients who met criteria for a primary end point.
b Patients who met multiple end points were counted only once in the total.
c When using a mixed model with site as a random effect, the odds ratio was 0.70 (95% CI, 0.52-0.94), confirming a benefit with genotype-guided dosing of warfarin.
(95% CI, 1.1%-5.8%) from a mean of 51.3% with clinically guided warfarin dosing to 54.7% with genotype-guided dosing ( Figure 4 and Figure 5 ). Genotyping especially benefitted the high-risk subgroup (P = .006 for interaction) in whom the improvement was 7.0% (95% CI, 3.4%-10.6%) from a mean of 48.4% (SD, 23.8%) with clinically guided dosing to 55.3% (SD, 23.4%) with genotype-guided dosing. The effect of genotype-guided dosing on PTTR was consistent in the 2 target INR groups (P = .053 for interaction) and among black participants (P = .48 for interaction). Between days 4 and 14 of warfarin therapy, genotype-guided dosing improved PTTR (absolute gain, 5.7% [95% CI, 2.2%-9.2%]; P = .005).
Protocol Adherence
Genotyping was completed prior to warfarin initiation for all but 1 patient. There were a total of 1068 dose deviations, representing 6.1% of the 17 567 doses recommended by the protocol. In the genotype-guided dosing group, 306 of 808 patients (37.9%) had at least 1 dose deviation; in the clinically guided dosing group, 349 of 789 (44.2%) had at least 1 dose deviation (P = .009).
One patient was lost to follow-up before the 30-day telephone call. Sixty-seven participants (36 [4.5%] in the genotypeguided group and 31 [4.2%] in the clinically guided group) did not undergo duplex ultrasound screening for DVT and were assumed to not have DVT.
Discussion
In this randomized clinical trial of warfarin thromboprophylaxis after hip and knee arthroplasty, genotype-guided dosing prevented more adverse outcomes than clinically guided dosing. The absolute reduction in the composite end point Compared with previous studies, [7] [8] [9] [10] [11] [12] [13] [14] this trial was larger, used genotype-guided dosing for a longer duration, and incorporated more genes into the dosing algorithm. Because the trial randomized approximately 1600 older patients (aged ≥65 years) undergoing arthroplasty, the effect of genotypeguided dosing was quantified for clinical outcomes rather than for PTTR alone. The trial used genotype-guided dosing for 11 days compared with only 4 or 5 days in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial 7 and in the EU-PACT 8, 9 and fewer days in other trials. [10] [11] [12] [13] [14] The longer period of genotype-guided dosing likely prevented cases of supratherapeutic INR that were common in these trials and during the second week of warfarin therapy in the clinically guided dosing group in this trial ( Figure 4) . Also, unlike prior trials performed at multiple centers, [7] [8] [9] this trial incorporated the CYP4F2 (V433M) SNP in the genotype algorithms.
Limitations
This study has several limitations. First, although participants and study personnel were blinded to study group and to genotype, the warfarin dose was open label. Therefore, study personnel may have been able to infer the study group, particularly in participants who only rarely needed dose adjustments. However, the warfarin dosing algorithms used in both of the study groups adjusted for many factors so dose estimates varied widely among patients in both the genotype-guided group and the clinically guided group. As a further protection against bias, the end points were adjudicated without knowledge of study group or genotype. Second, the 3.9% absolute reduction in the primary outcome (death, major bleeding event, INR ≥4, or VTE) was primarily related to differences in rates of INR of 4 or greater ( Figure 2 ). The 1.4% reduction in symptomatic major clinical adverse events (major bleeding, symptomatic DVT, or pulmonary embolism) did not achieve independent statistical significance (P = .051). Likewise, the risk of an INR exceeding the target INR by 1.5 or greater was not significantly reduced during the 90 days of follow-up (P = .08). Third, in this multicenter trial, most participants were enrolled at high-volume academic medical centers, which may limit generalizability. However, genotype-guided warfarin dosing may be more beneficial at low-volume hospitals, which may have higher rates of adverse events. 30, 31 Fourth, participants were aged 65 years or older. The benefits of genotype-guided dosing may differ when applied to patients of other ages or to general clinical practice. For example, advantages of genotype-guided dosing may be greater among populations in whom the VKORC1 and CYP2C9 SNPs are more common. 32 In contrast, the advantages of genotypeguided dosing may be diminished in populations with African ancestry because most genetic algorithms were derived primarily in populations composed of other races.
7,33
The benefits of genotype-guided dosing also may be reduced in patients who need to start warfarin before their genotype can be obtained. On the other hand, the benefits of genotype-guided dosing may be greater in clinical settings when warfarin initiation is dosed empirically rather than being guided by clinical algorithms.
Despite the requirement for INR monitoring, warfarin continues to be frequently prescribed because it is orally administered, inexpensive, and its effects are reversible. 34 However, there are alternatives to warfarin for VTE prophylaxis following orthopedic surgery. Aspirin is more convenient, albeit less effective at preventing VTE. 35, 36 Newer anticoagulants are effective; however, many physicians are reluctant to prescribe them due to their cost and risk of postoperative hemorrhage. 37, 38 Warfarin also remains the treatment of choice in patients with kidney failure. Therefore, strategies that optimize the risks and benefits of warfarin therapy are important despite the availability of alternatives. Widespread use of genotype-guided dosing will depend on reimbursement, regulations, and logistics. Although several commercial platforms for warfarin-related genes have been approved by the US FDA and the European Medicines Agency, routine genotyping is not yet recommended. 39 The Centers for
Medicare & Medicaid Services used its Coverage with Evidence Development program to fund genotyping in this trial and will review the results to determine future coverage. Based on data reflecting clinical care at the time, a 2009 decision analysis projected that genotype-guided dosing would cost less than $50 000 per quality-adjusted life-year gained in the population with chronic atrial fibrillation if it were available by the second warfarin dose, cost less than $200, and had an RR for major bleeding events of less than 0.68. 27 In this trial, the RR of 0.24 for major bleeding events (Table 3 ) had a wide 95% CI of 0.05 to 1.15, so the effect on major bleeding events is imprecise. In addition to incorporating more SNPs, 40 future research could focus on integrating warfarin dosing algorithms into electronic medical records.
Conclusions
Among patients undergoing elective hip or knee arthroplasty and treated with perioperative warfarin, genotype-guided warfarin dosing, compared with clinically guided dosing, reduced the combined risk of major bleeding, INR of 4 or greater, venous thromboembolism, or death. Further research is needed to determine the cost-effectiveness of personalized warfarin dosing.
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GIFT Investigators Aims and Hypothesis
The overall objective of the Genetics-InFormatics Trial (GIFT) of Warfarin to Prevent DVT is to elucidate novel strategies to improve the safety and effectiveness of warfarin therapy. With this study we directly respond to Health and Human Services (HHS) priorities to advance the field of personalized medicine and to prevent venous thromboembolic disease. Recently, the Honorable Mike Leavitt, Secretary of HHS, announced the Personalized Health Care Initiative and wrote that a key goal was, "… to use our personal genetic information to tailor treatments more effectively to each patient." 1 4, 5 In August 2007, the FDA approved the label change of warfarin/Coumadin™ to recommend considering lower initial doses in patients known to have certain polymorphisms in genes affecting warfarin metabolism and sensitivity. 6 However, whether this strategy improves the safety and effectiveness of warfarin therapy in general is unknown. In particular, how this strategy affects subgroups with and without the genetic variants of interest is also unknown. To test the resulting joint hypothesis while preserving an Aim-wide Type I error rate of < 0.05 we will partition our expected error rate as described in the methods section below.
Primary Joint hypothesis:
Pharmacogenetic therapy decreases the composite risk of a non-fatal VTE, non-fatal major hemorrhage, death, or INR>4.0 in all patients, and in the subgroup of patients whose pharmacogenetic and clinical predicted therapeutic maintenance doses differ by ≥ 1.0 mg/day (Appendix 4). Based on our meta-analysis of prior trials [7] [8] [9] [10] (Sections B.3 and B.7 of grant proposal) and our pilot studies (Section C of grant proposal), we anticipate 80% power to simultaneously detect a reduction in the composite outcome, as measured by a chi-square test in both populations. Hypothesis 2: For prevention of non-fatal VTE or death, a target INR of 1.8 will be non-inferior to a higher target INR (2.5). Using a non-inferiority margin of 3%, we will have 83% power to detect the non-inferiority of a target INR of 1.8 in 1600 patients.
Trial Overview
Over 4 years, GIFT of Warfarin will enroll 1600 orthopedic patients from Washington University in St. Louis, Intermountain Health Care, University of Utah Hospital, the Hospital for Special Surgery (Weill-Cornell, NYC), University of Miami, Rush University, and University of Texas Southwestern. Participants will be aged 65 years or older and scheduled for 4-6 weeks of warfarin therapy for venous thromboembolism VTE prophylaxis after elective hip or knee arthroplasty. After informed consent and genotyping, patients will be randomized to: (Aim 1) pharmacogenetic vs. clinical dosing of warfarin; and (Aim 2) a target INR of 2.5 vs. 1.8 ( Figure D.1 ) Figure 1 Overview of Randomization Randomization will be performed by the study website, WarfarinDosing.org and be stratified by study site, race, and type of joint replacement (hip vs. knee). WarfarinDosing.org will collect baseline information and display the therapeutic warfarin dose predicted by either a pharmacogenetic or clinical dosing algorithm, depending on treatment arm. WarfarinDosing.org has also been configured to prompt for regular INR follow up and adherence to the dosing protocol. This protocol is organized by the order in which information will be collected and/or transmitted (figure 2. illustrates this information flow). Orthopedic patients will be referred by their orthopedist to the Anticoagulation Service for warfarin initiation. The research coordinator will then contact the patient to explain the study and screen for eligibility. After informed consent, the coordinator will collect initial clinical data and three blood samples. He or she will enter the clinical data into the Warfarin Monitor database and WarfarinDosing.org. The coordinator will then send the 3 deidentified blood samples to the site's genotyping laboratory. After the laboratory technician has performed genotyping, he or she will enter the genotypes at www.WarfarinDosing.org. GIFT sites that do not have genotyping available locally will FedEx the blood samples directly to the GIFT Central Laboratory for genotyping. After the genotype has been entered, WarfarinDosing.org will email a dose (according to the study arm randomly assigned to the patient) back to the study pharmacist and the Study PI. This email will blind the researchers to genotype/Aim 1 study arm, but not to Target INR/Aim 2 study arm. A fourth blood specimen will be drawn on post-op day 2 and frozen for later study. The extra deidentified samples will be sent via FedEx on a regular basis to the central genotyping laboratory for genotype quality assurance, pre-operative warfarin-related analytic substudies, and long-term storage.
Inpatients will be monitored for adverse events daily by members of the clinical research team (section 8). During the telephone follow-up of INR values after discharge, adverse events will be collected systematically. If a symptomatic VTE has not been documented, patients will have a Doppler ultrasound at the time of their 3-7 week follow-up visit. Whenever possible, the Doppler US will be done within 6 weeks of arthroplasty. If a major hemorrhage, death, or symptomatic VTE has occurred (as determined locally to prevent delay in clinical follow-up, if necessary), the clinical coordinator will notify the participant's primary care physician, their local IRB, and the PI at Washington University. After local reading, the research team members will send the necessary documents and/or US images to the centralized event adjudicator, who will report back to the site clinical coordinator in case of discrepancy. Adjudication will be by a physician experienced in the interpretation of ultrasound images. While blinded to the original reading, the physician-adjudicator will interpret a sample of positive Doppler ultrasound reports and an equal number of negative ultrasound reports. After central adjudication and the resolution of any discrepant reports, the Biostatistics and Data Core will generate reports for the study PIs, and the IRB, regarding event rates of adjudicated outcomes (not stratified by arm). While the study PIs, IRB, clinicians and patients will remain blinded, the Data Safety and Monitoring Board (DSMB), will receive event rates stratified by trial arm. Updates on the trial status and trial observations will be made available through various means (Appendix 3). Trial data will be released to the public via PharmGKB (or similar passwordprotected public data base) 12 months after trial completion. 
Anticoagulation Services
The Anticoagulation Services are staffed by clinical pharmacists and physicians with expertise in warfarin therapy. WarfarinDosing.org will email these pharmacists with the predicted therapeutic doses, but genotype will be masked in this email.
Participant Eligibility Inclusion Criteria
Patients will be eligible to participate if they are aged 65 years or older, and anticipate taking warfarin therapy for 4-6 weeks for VTE prophylaxis after elective hip or knee arthroplasty. They must be able to give written, informed consent, have reliable telephone access, and be willing/able to followup in 3-7 weeks with a Doppler Ultrasound. Participants must have venous access, a life expectancy > 6 months, and plans to have regular INR monitoring.
Exclusion Criteria
We will exclude patients, who know their genotype or their therapeutic warfarin dose from prior therapy, or who refuse to give written consent. They must not have an absolute contraindication or allergy to warfarin therapy or plan to receive any anticoagulant besides warfarin (except heparin flushes). However, if LMWH, fondaparinux, or subcutaneous heparin is deemed necessary by the clinician after enrollment, such patients will remain in the study. Participants must not be incarcerated or institutionalized at the time of enrollment, or unlikely to be compliant (e.g. due to history of noncompliance or alcoholism), but nursing home residents are eligible to participate. Use of antiplatelet therapy (e.g. aspirin, dipyridamole, ticlopidine, clopidogrel, or prasugrel) will be allowed, as clinically indicated. As in the pilot studies, use of intermittent compression devices will be allowed for inpatients (but not used after hospital discharge). Patients with known thrombophilia, a bleeding disorder, a serious bleed in the past 2 years unless caused by trauma, or a baseline INR > 1.35 will be excluded because it would be unethical to randomize them to the 2 target INR ranges. Patients will not be recruited if their clinicians are of the opinion that warfarin dosing needs to be adjusted for any reason not accounted for by the dosing algorithms.
Participant Recruitment and Involvement (see also Protection of Human Subjects)
As in the pilot studies, we will recruit patients who plan to undergo knee or hip replacement surgery. Sites will include Washington University in St. Louis, Intermountain Health Care, University of Utah Hospital, the Hospital for Special Surgery (Weill-Cornell, NYC), Rush University, and University of Texas Southwestern. Orthopedic patients will be recruited upon initial evaluation for total hip or knee arthroplasty, at the group education meeting that they attend pre-operatively, or in the preadmission testing pre-operatively. After written consent, an extra 11 ml of blood for research purposes will be drawn with their pre-operative labs. If blood is not available, then saliva or a buccal swab may be used for DNA recovery.
Recruiters will be provided with a checklist of inclusion and exclusion criteria, as well as a sample recruitment script. The consent process will begin with a verbal description of the study, the risks and benefits of participating in the study, confidentiality of health information, and the right to refuse or withdraw participation without consequence at any time. Informed consent will be obtained by study pharmacists or other personnel certified by the IRB (coordinators, research assistants) to recruit patients. Because we are not asking sensitive questions, nor testing for paternity, HIV, or illicit drug use, we will not provide a certificate of confidentiality. Recruiters will be trained to answer questions about the protocol and consent forms.
Folders for potentially recruited patients will be prepared in advance and will contain blank consent forms, intake questionnaires, eligibility checklist, a recruitment script, and INR/dose monitoring forms (a paper-based copy of the daily information collected in warfarin monitor) affixed with a unique study identifier. Concomitant anticoagulant and antiplatelet agents will be recorded in case report forms. In addition, the timing of the warfarin dose will be standardized and recorded and the time of each blood draw will be noted on each specimen. Folders for each consented participant will be maintained and data from each folder will be entered into the Warfarin Monitor database and www.WarfarinDosing.org. The recruiters (or hospital phlebotomist in the presence of the recruiter) will collect the blood specimens at the time of recruitment, label the specimens with the study ID, and send them to the local genotyping lab for processing. They will then enter clinical data into Warfarin Monitor and www.WarfarinDosing.org. The genetic laboratory assistants will enter genotype separately onto the website; they will be trained to withhold communication about the genotype of particular patients from the pharmacists and research assistants. When feasible, a fourth 3 mL blood specimen will be drawn on post-op day 2 and also sent to the local genotyping laboratory and frozen for later study (of S-and R-warfarin levels, high-sensitivity C-reactive protein [hs-CRP], IL-6, high-sensitivity cardiac troponin I (hs-cTnI), and clotting factors). The deidentified blood specimens will be sent to the Central Genotyping Laboratory via FedEx for genotyping, analyte substudies, and DNA archiving.
Inpatients will be monitored for adverse events daily by members of the clinical research team (section 8). During the telephone follow-up of INR values after discharge, adverse events will be collected systematically. If a major hemorrhage or symptomatic VTE has not been documented clinically, patients will have a Doppler ultrasound at the time of their 3-7 week follow-up visit.
Together, the participating sites initiate warfarin therapy on at least 13,000 orthopedic patients per year. Our refusal rate averages 6-7%, and the drop-out rate (due mainly to change in orthopedic procedure after recruitment) is < 10%. Thus, we plan to recruit 1600 participants.
Randomization and Blinding

Randomization
Using a 2 x 2 factorial design, we will randomize patients to each of the following:
(
1) Pharmacogenetic (50%) vs. clinical dosing of warfarin (50%); and (2) a standard target INR (2.5) (50%) vs. a lower target INR (1.8) (50%)
This randomization scheme allows us to answer two essential questions about VTE prevention in this high-risk population (Aims 1-2). To allow for randomization stratified by site, race, and type of arthroplasty (knee vs. hip), www.WarfarinDosing.org will randomize patients after these data have been entered by clinical coordinator. Lists for block randomization will be prepared in advance by the trial statistician, and monitored to ensure proper function.
Blinding
To maintain double-blinding to genotype, www.WarfarinDosing.org will randomize participants to pharmacogenetic or clinical dosing and email the recommended warfarin dose to the study pharmacist and PI. Thus, these clinicians will receive an email with the estimated dose tailored to genotype and/or clinical factors, but the genotype will be masked. We acknowledge that rare genotypes will require unusually small doses, potentially leading to unblinding. However, because so many factors affect warfarin dose besides genotype, inadvertent unmasking will be rare. Randomization to standard vs. lower target INR value will not be double blinded because clinicians must know patients' target INR to monitor their INR properly. Bleeding and VTE events will be assessed locally (blinded to genotype), so that any clinical action deemed necessary may proceed without delay and appropriate IRBs can be notified. Event reports and/or deidentified portions of the medical record will then be sent to the central adjudicators, who will be blinded to both genotype and target INR, for confirmation. The central adjudicators' adjudications will follow standardized guidelines and be considered final for analysis purposes (see section10 for details). Collaborating orthopedic surgeons will be blinded to the genotype and study arm (pharmacogenetic or not) of participants, but not target INR.
Rules for Unblinding
We will not include genotyping results in the patient's medical record nor provide them to study participants nor their physicians. All procedures during the unblinding process will be reported to the study PI and DSMB, where they will be documented. The DSMB will have access to unblinded data, when requested, for evaluating and/or reporting on patient safety during the conduct of the trial. The consent form will contain language that makes our intent clear to participants.
Algorithm-Based Dosing of Warfarin
The genetic and clinical dosing algorithms have been published [13] [14] [15] [16] [17] or are in the manuscript writing stage and have been programmed into WarfarinDosing.org. The algorithms use the following polymorphisms to estimate the therapeutic warfarin dose among participants randomized to genetic dosing: VKORC1*2 (-1639 G>A, dbSNP rs9923231), CYP2C9*2 (430C>T, dbSNP rs1799853), CYP2C9*3 (1075A>C, dbSNP rs1057910), and CYP4F2*3 (V433M, 1297G>A, dbSNP rs2108622).
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The anticoagulation service or managing physician will enter warfarin doses and INRs for the initial 11 days of therapy for each participant using a unique patient ID. The website will then calculate a dose refinement based on this information as well as the study arm and genotype (when applicable). The genotype and study arm will be electronically stored in the background and not visible by the pharmacist seeking a dose-refinement. The effect of warfarin will be assessed by the INR. For this measure, a 3-or 4.5-ml blood sample will be collected by venipuncture into a vacutainer containing 0.5 ml of 3.2% sodium citrate and centrifuged to obtain plasma for analysis. Prothrombin times will be performed on automated coagulation instruments (e.g. STAR™) using a thromboplastin with an international sensitivity index < 1.5. Point-of-care (POC) INR testing will be allowed. The frequency of INR monitoring will be per protocol (Table D. 1). Deviations from this schedule will be made if deemed clinically necessary as determined by protocol (i.e., for bleeds, after dose adjustments, or following INR values > 3.5) and when a national holiday falls on a Monday or Thursday. Inpatients will have daily INR measurements, as is standard of care post joint replacement.
Standardization of INR Monitoring
Standardization of Dosing Protocol & Event Monitoring
After randomization, but prior to surgery, WarfarinDosing.org will be used to predict a therapeutic warfarin dose (either based on the clinical or the pharmacogenetic algorithm 15 ) for each patient. The initial dose will be administered to participants starting the day before or the night of surgery (depending on local practice). CYP2C9 variants will be ignored during the 1 st two days of therapy. This convention, which is based on pharmacokinetic modeling and our prior work, 15 prevents under-dosing slow metabolizers. It also allows clinicians to remain blinded to study arm, even in patients who have usual CYP2C9 genotypes. After two warfarin doses, the research coordinator will enter the warfarin doses and INR (called "INR 2 ") into www.WarfarinDosing.org. The website then estimates a refined estimate of the therapeutic warfarin dose that incorporates INR 2 and genotype (for patients in the pharmacogenetic arm). Then, each day that an INR is available, the researcher will enter INR value and get a refined dose estimate up to day 11 of warfarin therapy. On days when the INR is not drawn, patients will continue to receive their estimated maintenance dose. WarfarinDosing.org also indicates whether the dose of warfarin given on the day of INR testing should differ from the estimated therapeutic dose. This feature (called "Today recommendations") allows WarfarinDosing.org to compensate for missed doses, large doses, or other dosing errors.
Clinicians will be allowed to round up or down to the nearest 1 mg (for doses > 3 mg/day) or 0.5 mg (for doses < 3.0 mg/day) at their clinical discretion. If the clinician overrides this protocoldefined dose, he or she will receive prompting by the website to adhere to the protocol (unless a deviation is clinically indicated). When necessary (e.g., an INR > 5), low-dose oral vitamin K will be administered to reverse the effects of warfarin, as clinically indicated.
Inpatients will be monitored by the study coordinators for warfarin-related adverse events daily until hospital discharge. During the hospital stay, recommendations for warfarin doses will also be made daily by the study pharmacist or managing physician. Thereafter, the coordinator will monitor for adverse events (including VTE and, bleeding) whenever an INR is checked (per schedule in Table  D.1) . Patients who stop their warfarin prematurely should be called weekly through day 30 to assess for study outcomes and adverse events. All patients also should be called after 30 days and 90 days of follow-up to assess for study outcomes and adverse events. Serious adverse events will be immediately reported to the IRB and DSMB (if the DSMB requests this information). Patients will be given a list of potential adverse effects and telephone numbers to report adverse events to the study pharmacist or managing physician. Patients will be given warfarin for 4-6 weeks after hospital discharge and scheduled to return for Doppler screening of leg veins 3-7 weeks after the date of surgery (when they have their routine follow up).
Event Definitions Major Bleeding
As per the Control of Anticoagulation Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) definition, 21 all major bleeds must be symptomatic or clinically-overt according to 3 criteria:
1. Fatal bleeding defined as bleeding that has been adjudicated as the cause of patient death by a panel of experts blinded to treatment and study arm, and/or 2. Overt bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, joint or soft tissue hematoma requiring return to the operating room, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or 3. Overt bleeding causing a fall in hemoglobin* level of 20 g/L (i.e., 2 g/dL or 1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.
*we will use post-op day 1 Hgb as "baseline" because this value accounts for intra-operative blood loss and volume resuscitation in the OR.
Because the threshold for blood transfusion has evolved 22 23 since the ISTH guideline was formulated, GIFT also will classify as "major" any bleed that meet this fourth criterion:
4. An overt bleed causing hemodynamics changes and leading to transfusion of 1 or more units of blood. The number of additional major bleeds identified by criteria #4, will be reported.
Minor Bleeding
We will report minor bleeding, defined as bleeding that is neither major nor occult using the following categories:
1 
Venous Thromboembolic Event (VTE)
VTE includes any DVT or PE that has been objectively confirmed by a Doppler US, venography, pulmonary-perfusion scan, spiral CT scan, MRI, or pulmonary angiogram; an elevated DDimer test will not be sufficient for a diagnosis of VTE. We will screen for asymptomatic DVT by Doppler US 3-7 weeks post-operatively. Using the classic method, 26 DVT examination will consist of comprehensive venous compression, color flow imaging, and pulse wave evaluation with augmentation of the common femoral, superficial femoral, popliteal veins, and calf veins at 2-cm intervals in the transverse plane. A positive Doppler is defined by the detection of any noncompressible intraluminal venous thrombus; adjunct measures of a positive Doppler will include lack of color flow and diminished augmentation.
Myocardial Infarction (MI)
An event will be considered an MI when "there is evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia" 27 . Under these conditions any one of the following criteria meets the diagnosis for myocardial infarction:
Detection of rise and or fall of cardiac biomarkers (per the ACC/AHA guidelines, preferred cardiac biomarker is troponin) with at least one value above the 99 th percentile of the upper reference limit together with myocardial ischemia with at least one of the following: a. Symptoms of ischemia b.
ECG changes indicative of new ischemic (new ST-T changes or new left bundle branch block) c.
Development of pathological Q waves in the ECG d.
Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
The 99% percentile of the upper reference limit will be assay specific. For example, using the current reagents at Barnes-Jewish Hospital, the upper limit will be > 0.07 ng/ml.
Adjudication of Outcomes
First, major bleeds or VTEs will be assessed by the local research coordinator and site PI, both of who will be masked to genotype and to PGx vs. clinical treatment assignments. To provide double data entry of the primary outcomes, www.WarfarinDosing.org will also solicit INR, warfarin dose, and clinical outcomes if not entered at 30 days of follow up. Next, deidentified event reports, including the relevant portions of the medical record or of ultrasound images (if available for review) will then be sent to the centralized event adjudicators for validation. Central adjudicators will be blinded to genotype, Target INR, study arm, and warfarin doses.
The safety outcomes will be major bleeding (as defined above, Section 9), and the occurrence of INR≥4.0 within 30 days of arthroplasty. The effectiveness outcomes will be nonfatal VTE (including asymptomatic DVTs found by Doppler ultrasound within 60 days of arthroplasty) or death within 30 days of arthroplasty. Patients who develop a nonfatal efficacy or safety outcome will continue followup until the end-of-study assessment except that a Doppler US will not be done in patients who already have had an incident VTE documented.
Timeframe for Study Endpoints
The study is a 2 x 2 factorial design. The primary endpoint for Aim 1 is the composite of nonfatal VTE (DVT or PE), major hemorrhage, INR>4.0, or death occurring with 30 days of arthroplasty. Because the date of onset of VTE is ambiguous in the post-operative setting (and depends on the date of the Doppler US screening), VTEs diagnosed within 60 days of arthroplasty will be included in the primary endpoint.
The primary endpoint for Aim 2 is the composite of nonfatal VTE or death. We opted to include all-cause death in the endpoint (as opposed to vascular death) because cause of death may not be discernable. Primary analyses for both aims will be on an intent-to-treat basis, but we also will report an on-treatment analysis. 
Effect of Censoring on the Analysis of the Primary Outcomes
Withdrawal or loss to follow-up may occur either due to circumstances unrelated or related to the trial. We will plot time to study discontinuation in the study arms and compare them using the logrank test. The frequency of INR testing and dose-adjustment will be captured and analyzed in all patients (including study dropouts). In pilot studies at Washington University, which were observational, the rate of withdrawal was 3.4%, but we anticipate a higher drop out in this randomized trial. Subjects who withdraw from the study after randomization will be included in the analyses on an intent-to-treat basis. Because all aims will benefit from completion of the trial, we do not plan an interim analysis, but the DSMB has authority to stop the trial in the event of unexpectedly high number of serious adverse events.
Power and Statistical Analyses of Primary Endpoints Aim 1. Primary endpoint for clinical vs. pharmacogenetic warfarin dosing
For Aim 1, our composite endpoint is VTE (DVT or PE), death, major bleed, and an INR>4.0. We will analyze the primary endpoint in the whole population and in the subpopulation whose clinical and genetic predicted doses differ by > 1.0 mg/day (50% of the population) using a two-sided chisquare test. For the primary analysis, we opted not to weigh clinical events due to complications relating to the arbitrariness of weights or non-linear trends in the frequency of endpoint severity (see secondary analyses). To preserve the type I error rate of this primary endpoint, we will partition our alpha for the tests in the whole group and the subgroup, as described below.
We hypothesize that the rate of VTE in the subpopulation whose clinical and genetic predicted doses differ by > 1.0 mg/day will be 1.6 times as high as that of the remaining population. The 1.6-fold increase accounts for a greater rate of adverse events in patients who have genetic variants, especially CYP2C9*2 and/or CYP2C9*3.
We originally estimated VTE rates of 18% in patients randomized to clinical dosing and 15% in patients randomized to genetic dosing based on older data. [28] [29] [30] [31] In the clinical arm, we originally anticipated a rate of major bleeding as 2.4% and rate of death as 1.0%, for a total of 3.4%. In the pharmacogenetic arm, we anticipated the rate of major bleeding or death as 2.3%, a 32% relative risk reduction based on a meta-analysis of clinical trials 32 and observational studies. 16, 33 We had estimated the rate of INRs > 4.0 in clinical and pharmacogenetic arms from previous research 16 as 12.3% and 7.4% respectively. We anticipate that half of the bleeding events will be associated with INRs > 4.0, and account for this correlation in our original and updated power calculations. When GIFT was planned, the expected rate of the composite endpoint (non-fatal VTE, nonfatal major hemorrhage, death, or INR>4.0) in Aim 1 was estimated as 27.3%. This rate would have provided a power of 99% for a sample size of 1600 participants. Midway through the trial (when data from 775 GIFT participants were available), the composite endpoint in Aim 1 was observed to be 13.15%, which provides for a power of 80%.
The 80% power was calculated using a two-sided alpha of 0.05 for a test of proportions, a drop-out rate of 2%, a modest (5%) correction for continuity, and assuming the 32% relative risk reduction (RRR) in adverse events from our original meta-analysis, 32 which yielded estimated rates of 10.7% in the pharmacogenetic arm and 15.7% in the clinical arm. The 80% power includes use of the partitioned alpha with 0.044 allocated to the whole population and 0.01 to the high-risk subgroup. Because of correlation between these two subgroups, using these alphas preserves an overall type 1 error rate of 0.05.
Alpha partitioning
To preserve a Type 1 error rate of 5% for Aim 1, we will partition the alpha between the whole group analysis and the subgroup analysis. The subgroup consists of patients for whom PGx and clinical doses differ by 1+ mg/day. Due to correlation between outcomes in main study and subgroup, Bonferroni splitting would be overly conservative. Due to the lack of a closed equation, we simulated this correlation to allocate the alpha optimally. In the table (below) ' whole ' is the alpha spent by the test of the whole group (and should be ~0.05). ' sub ' is the alpha spent by the test of the subgroup. ' total ' is the total alpha (=sum minus intersection of the probability spaces) of these correlated tests. Partitioning the alpha in this manner maximizes power for Aim 1 while limiting the overall type 1 error rate to 0.05. We elected to partition the alpha according to the highlighted row above, as it maximizes the power for the test in the whole group, without jeopardizing the power in the subgroup.
Aim 2. Primary endpoint for low vs. high target INR
We hypothesize that orthopedic patients randomized to a target INR of 1.8 will have a rate of VTE or vascular death that is non-inferior to a target INR of 2.5. Using the average of our estimates above, we had expected the rate of VTE (including fatal events) with warfarin therapy and Doppler US screening to be 16.5%, which yielded the original power calculation (see appendix). Based on the aggregate (blinded) analysis done half-way through GIFT, we observed that the VTE rate averaged only 5.56%, which increased the power for this non-inferiority analysis. Therefore, we were able to decrease the non-inferiority margin from the original value (5%), to a more stringent one (3%), while increasing our power from 80% to 83%. For the updated power calculation, we used a sample size of 1600 participants, drop-out rate of 2%, and non-inferiority margin of 3%. For this calculation, we used a one-sided test (because we are testing for non-inferiority) and a minimum absolute difference of 3% in VTEs detectable by Doppler US.
Differences of VTEs of < 3% (as detected by screening) seem unlikely to motivate orthopedic surgeons and other physicians to use a therapy with a higher risk of hemorrhage. For example, LMW heparins have a 3% lower absolute rate of VTEs (on venography), yet warfarin remains more popular in the US, because of its lower rate of hemorrhage, oral administration, and low cost.
Contingency plan for statistical analyses.
For both aims, if the expected counts in any cell are less than 5, we will use a Fisher's exact test. If by chance randomization were to result in an unbalanced distribution of any clinical variable associated with VTE [i.e., age, body mass index, hormonal replacement therapy, or male gender 34 ], we would adjust for the unbalanced variables using logistic regression. Analyses will be performed in SAS, version 9.1.3 or greater or in R.
Secondary Outcomes and their Statistical Analyses
1 Percentage of Time in Therapeutic Range (PTTR)
We will compare percentage time spent in therapeutic range (PTTR) during days 4-28 of warfarin therapy for pharmacogenetic vs. clinical dosing in a regression model that uses linear interpolation, as recommended. 35 If there is no INR measured on day 28, but there is an INR measured later (e.g. day 29), then the latter INR will be used so that the analysis can be completed for days 4-28 of therapy. Our approach to missing data (Table D. 3) is based on that used by the COAG investigators (Table 3) : Compute PTTR with available INRs up through 5 days after discontinuation.
A "restart" is defined as starting warfarin after it had been held for at least 1 day. For patients who have the drug held for 5 days or fewer, all available INRs will be used in the calculation of the PTTR. For those who have the drug held for more than 5 days, any INRs measured in the 5 days after the drug was held will be used in the calculation of PTTR. Once the drug is restarted, the first INR drawn will then be used to calculate PTTR from that point on. The overall PTTR will be concatenated between the courses of warfarin therapy; that is, for both short and longer term holds, a single PTTR will be calculated for a patient using all INRs available during the time on warfarin. For patients who have their warfarin permanently discontinued, the PTTR will be calculated using all INRs through 5 days after discontinuation.
We will also conduct a separate analysis of time supratherapeutic (i.e. >0.5 units more than the target INR) during the first 28 days of warfarin. In that analysis we will test for an interaction between the study arm in Aim 1 and CYP2C9 genotype. Specifically, we will code 2C9*1*1 as 0, 2C9*1*2 as 1, 2C9*1*3 or 2C9*2*2 as 2, 2C9*2*3 as 3, and 2C9*3*3 as 4 because the effect of the 2C9*3 allele on warfarin metabolism is approximately twice the 2C9*2 effect.
INR Variability
We will report INR variability, defined as the standard deviation of transformed INR values from days 4-28 of therapy, calculated according to the method of Lind et al. 36 
Time to First Event
We will compare time to first laboratory event (number of days until INR > target INR + 1.5) graphically (using Kaplan-Meier curves) and statistically (using the log-rank test, Wilcoxon test, or Cox-proportional hazard model), as appropriate. We will censor participants at the time of withdraw, loss to follow-up, death from an unrelated event, or 90-days of follow-up (whichever come first).
Likewise, we will compare time to the first major or non-major, clinically relevant bleed that is clinically relevant (safety endpoint) within 90-days of follow up.
Secondary Statistical Analysis of Primary Endpoint in Aim 1
As a secondary outcome, we will analyze the rank of events and test the hypothesis that genetic dosing decreased the rank of adverse events vs. clinical dosing in the whole cohort. We will use the following tiers, in hierarchical order, from worst to best: (1) favored this approach, rather than using weighted outcomes, because it avoids assigning ad hoc weights to these adverse events.
Secondary Analyses for Aim 2
We also will report the secondary analyses above for the two arms in Aim 2. Furthermore, we will compare the two arms in Aim 2 using the same composite outcome from Aim 1: VTE (within 60 days), or any of the following within 30 days: major hemorrhage, death, or INR > 4.0.
Potential Problems and Their Resolution Incorporating New Variants into Pharmacogenetic Arm
We recognize that we or others may discover additional relevant SNPs during the course of the trial and will establish criteria for whether these SNPs are clinically relevant. The primary metric for this decision will be whether this SNP has been validated to warrant scientific agreement of its effect as well as the ability of the new and validated SNP to decrease the prediction error of the pharmacogenetic algorithm in affected individuals by some minimum threshold. We will also need to establish the frequency of such variants in the subgroups studied in the trial, and determine whether a minimum allele frequency should also be established, so that the overall effect (as measured by the R 2 ) improves significantly in a clinical and statistical manner (e.g. 1%).
If a variant improves the predictive accuracy significantly, the pharmacogenetic algorithm would be modified. This adjustment would be easily incorporated by the website, since all predictive variables translate to multipliers in the dosing algorithm. For example, if we find a variant whose effect in carriers is to increase the necessary dose by 20%, we would program WarfarinDosing.org to apply the 1.2 multiplier where appropriate. For common SNPs, a complementary dose adjustment would be made to the non-carriers. Our positive working relationship with Osmetech's eSensor, Pyrosequencing, and Autogenomics' INFINITI™ will facilitate the implementation of a rapid genotyping platform for any new SNP warranting pharmacogenetic implementation as well. 
Data Sharing and the Dissemination of Results
As detailed in Appendix 3, we will disseminate the results of the trial using the Internet, traditional medical publications, professional societies, lay press, and collaboration with the FDA. We will register the trial following instructions at http://prsinfo.clinicaltrials.gov/registering.pdf, and regularly update information pertaining to its status. One year after the completion of the trial and data analysis, we will release the trial data to the public via the PharmGKB site maintained at Stanford University or equivalent site. We will submit the methods of the clinical trial for publication.
Archiving of DNA and Blood for Subsequent Analyses
DNA and plasma from the proposed study will be archived at the central genotyping laboratory for subsequent studies of SNPs or biomarkers that may affect bleeding or VTE, and SNPs or biomarkers that may further influence warfarin dosing. These future studies may include whole genome association studies, or candidate gene studies about warfarin dosing, thrombosis, or hemorrhage. We also will archive blood for future pharmacokinetic modeling, and (possible) future proteomic and metabolomic studies about hemorrhage and VTE.
p. 3 and 14. Non-inferiority Margin has been changed to 3% Previous: "Hypothesis 2: For prevention of non-fatal VTE or death, a target INR of 1.8 will be noninferior to a higher target INR (2.5). Using a non-inferiority margin of 5%, we will have 80% power to detect the non-inferiority of a target INR of 1.8 in 1600 patients." Change: "Hypothesis 2: For prevention of non-fatal VTE or death, a target INR of 1.8 will be noninferior to a higher target INR (2.5). Using a non-inferiority margin of 3%, we will have 83% power to detect the non-inferiority of a target INR of 1.8 in 1600 patients." Rationale: Previously, the statisticians pointed out that given the lower rate of VTE and death in GIFT, that a non-inferiority margin of 5% (in the absolute event rate) was too high. Using a 3% noninferiority margin, we estimated a power of 83% with 1600 enrollees. We used a one-sided alpha of 0.05 for a non-inferiority test of proportions, composite rates of 5.56%, and a drop-out rate of 2%. Rationale: Sometimes the orthopedic follow-up visit occurs after 6 weeks, so the ultrasound (US) is late. We now make explicit that DVTs diagnosed on or before 60 days post-operatively will be included in the primary outcomes for both Aims. This delay is the reality of getting an US test in elderly patients who cannot drive in the post-op period. p. 5. Patients with a prior bleed caused by trauma are no longer excluded from GIFT Previous: "Patients with known thrombophilia, a bleeding disorder or serious bleed in the past 2 years, or a baseline INR > 1.35 will be excluded because it would be unethical to randomize them to the 2 target INR ranges." Change: "Patients with known thrombophilia, a bleeding disorder, a serious bleed in the past 2 years unless caused by trauma, or a baseline INR > 1.35 will be excluded because it would be unethical to randomize them to the 2 target INR ranges." Rationale: Patients with non-traumatic bleed will continue to be ineligible for GIFT because there is not clinical equipoise re: which target INR they should use-many clinicians prefer a lower target INR for this population. This preference does not extend to patients whose only major bleed in the past 2 years was due to trauma. Therefore, the latter patients are still eligible to participate in GIFT.
the ISTH guidelines were written (2005), patients with overt bleeding causing hemodynamics changes typically would have been transfused at least 2 units of packed RBCs. Now, these patients often receive only a single unit of blood. 22 23 The fourth criteria allows these bleeds to be capture as major, p. 14 The power analysis for Aim 2 was revised, based on the lower-than-expected VTE rates observed half-way through the trial Previous: "If we recruit 1600 participants (800 each for greater and lesser INR targets), and assume an 18% drop-out rate, we will have 1312 participants left for analysis. Using these figures, we will have 80% power to reject the null hypothesis of a difference greater than 5% (the non-inferiority margin) in the two arms." Change: "Using the average of our estimates above, we had expected the rate of VTE (including fatal events) with warfarin therapy and Doppler US screening to be 16.5%, which yielded the original power calculation (see appendix). Based on the aggregate (blinded) analysis done half-way through GIFT, we observed that the VTE rate averaged only 5.56%, which increased the power for this noninferiority analysis. Therefore, we were able to decrease the non-inferiority margin from the original value (5%), to a more stringent one (3%), while increasing our power from 80% to 83%. For the updated power calculation, we used a sample size of 1600 participants, drop-out rate of 2%, and noninferiority margin of 3%." Rationale: Given the observed VTE rate mid-way through GIFT, a non-inferiority margin of 5% would not have been sufficiently stringent.
p. 14-15, Section 13, Secondary Outcomes and their Statistical Analyses Previous: "We will compare time spent in therapeutic range (PTTR) during the first 30 days of warfarin for pharmacogenetic vs. clinical dosing in a regression model using linear interpolation, as recommended. 35 " Change: "We will compare percentage time spent in therapeutic range (PTTR) during days 4-28 of warfarin therapy for pharmacogenetic vs. clinical dosing in a regression model that uses linear interpolation, as recommended. 35 If there is no INR measured on day 28, but there is an INR measured later (e.g. day 29), then the latter INR will be used so that the analysis can be completed for days 4-28 of therapy. Our approach to missing data (Table D. 3) is based on that used by the COAG investigators (Table 3) : A "restart" is defined as starting warfarin after it had been held for at least 1 day. For patients who have the drug held for 5 days or fewer, all available INRs will be used in the calculation of the PTTR. For those who have the drug held for more than 5 days, any INRs measured in the 5 days after the drug was held will be used in the calculation of PTTR. Once the drug is restarted, the first INR drawn will then be used to calculate PTTR from that point on. The overall PTTR will be concatenated between the courses of warfarin therapy; that is, for both short and longer term holds, a single PTTR will be calculated for a patient using all INRs available during the time on warfarin. For patients who have their warfarin permanently discontinued, the PTTR will be calculated using all INRs through 5 days after discontinuation."
Rationale:
The above approach maximizes use of INR data while mitigating the effect on PTTR when warfarin is held > 5 days. The study sites were told to have the follow-up intervals described above. Change: "Patients who stop their warfarin prematurely should be called weekly through day 30 to assess for study outcomes and adverse events. All patients also should be called after 30 days and 90 days of follow-up to assess for study outcomes and adverse events." Rationale: To prevent ascertainment bias, patients who stop their warfarin early should be followed with equal frequency. The 90-day outcomes has been part of GIFT since the 1st patient was recruited, but the protocol was not explicit. ) screened for DVT using a more sensitive test, venography, we estimate that an 18% VTE rate will be detected by Doppler US screening in GIFT. The rate of VTE with pharmacogenetic-dosed warfarin also is uncertain. In our pilot study, 31 the rate of DVT was 11.5%, but the 95% confidence interval was large. For GIFT, we estimated a 15% VTE rate in participants dosed pharmacogenetically. We suspect that the rate of VTE in the subpopulation whose clinical and genetic predicted doses differ by > 1.0 mg/day will be 1.6 times as high as that of the remaining population. The 1.6-fold increase accounts for a greater rate of adverse events in patients who have genetic variants, especially CYP2C9*2 and/or CYP2C9*3.
Compared to VTEs, major bleeds and deaths will be uncommon. In the clinical arm, we anticipate that the rate of major bleeding will be 2.4% and the rate of death will be 1.0%, for a total of 3.4%. In the pharmacogenetic arm, we anticipate the rate of major bleeding or death will be 2.3%, a 32% relative risk reduction based on a meta-analysis of clinical trials 32 and observational research. 16, 33 We used one of these observational studies 16 to estimate the reduction in supra-therapeutic INR values. We estimated the rate of INRs > 4.0 in clinical and pharmacogenetic arms from previous research in this area as 12.3% and 7.4% respectively. We anticipate that half of the bleeding events will be associated with INRs > 4.0, and account for this correlation in our power calculations. If we recruit 1600 participants (800 each for pharmacogenetic and for clinical arms), and assume an 18% drop-out rate, we will have 1312 participants left for analysis. Using these figures and partitioning our alpha to preserve an overall Type I error rate of 0.05 for the primary endpoints in Aim 1, we calculate 99% power to detect a difference in the rate of the composite endpoint between clinical and pharmacogenetic arms in the whole population or the subgroup.
Change: Aim 1. Primary endpoint for clinical vs. pharmacogenetic warfarin dosing
…We hypothesize that the rate of VTE in the subpopulation whose clinical and genetic predicted doses differ by > 1.0 mg/day will be 1.6 times as high as that of the remaining population. The 1.6-fold increase accounts for a greater rate of adverse events in patients who have genetic variants, especially CYP2C9*2 and/or CYP2C9*3.
We originally estimated VTE rates of 18% in patients randomized to clinical dosing and 15% in patients randomized to genetic dosing based on older data [28] [29] [30] [31] . In the clinical arm, we originally anticipated a rate of major bleeding as 2.4% and rate of death as 1.0%, for a total of 3.4%. In the pharmacogenetic arm, we anticipated the rate of major bleeding or death as 2.3%, a 32% relative risk reduction based on a meta-analysis of clinical trials 39 and observational studies 16 . We had estimated the rate of INRs > 4.0 in clinical and pharmacogenetic arms from previous research 16 as 12.3% and 7.4% respectively. We anticipate that half of the bleeding events will be associated with INRs > 4.0, and account for this correlation in our original and updated power calculations. When GIFT was planned, the expected rate of the composite endpoint (non-fatal VTE, nonfatal major hemorrhage, death, or INR>4.0) in Aim 1 was estimated as 27.3%. This rate would have provided a power of 99% for a sample size of 1600 participants. Midway through the trial (when data from 775 GIFT participants were available), the composite endpoint in Aim 1 was observed to be 13.15%, which provides for a power of 80%.
Rationale:
The rationale for the above changes is to make explicit the original and updated power for Aim 1. The primary outcomes, sample size, effect size (32% relative risk reduction), and proposed analytic approach have not changed. The genetic dose (on day 1) also was adapted from Gage et al. where the SNPs (VKOR_1639G>A, CYP2C9*3, CYP2C9*2, CYP4F2_Factor) are coded 0 if absent, 1 if heterozygous, and 2 if homozygous. CYP4F2_Factor accounts for the V433M polymorphism 20 with a coefficient that is slightly greater among patients who self-identify as black or African-American: 0.82 * Number of participants with one or more adverse events (AE) other than major bleeds, venous thromboembolism, or elevated international normalized ratio values. Participants who had multiple events are counted only once in the bolded rows. For example, a patient who had both post op myocardial infarction and atrial fibrillation is counted only once in the bolded row titled, "Cardiovascular Event." † Stitch abscesses without sequelae are not included as infections.
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